The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial of pemetrexed plus oxaliplatin as =2nd-line therapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin based chemotherapy.
 
Jwa Hoon Kim
No Relationships to Disclose
 
Changhoon Yoo
Honoraria - AstraZeneca; Bayer; Boryung Pharmaceuticals; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; MSD Oncology; Novartis; Roche/Genentech; SERVIER
Research Funding - AstraZeneca; Bayer; Boryung Pharmaceuticals; CKD pharm; Eisai; Lunit; SERVIER
 
Hyehyun Jeong
No Relationships to Disclose
 
Jaekyung Cheon
No Relationships to Disclose
 
Kyu-Pyo Kim
No Relationships to Disclose
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Heung-Moon Chang
Research Funding - Astellas Pharma (Inst); Taiho Oncology (Inst); Zymeworks (Inst)
 
Chungryul Oh
No Relationships to Disclose
 
Hyewon Ryu
No Relationships to Disclose
 
Inkeun Park
Consulting or Advisory Role - Amgen; Astellas Pharma Korea; BMS pharmaceutical Korea; Boryung Pharmaceuticals; Chong Kun Dang Pharmaceutical Co; daiichi sankyo korea; Janssen; Merck; Ono Pharmaceutical; Samsung Bioepis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Boryung Pharmaceutical Co (Inst); Chong Kun Dang Pharmaceutical Co. (Inst)